Anticancer activity of hypericum mysorense

Abstract

Methanolic extracts of different parts of Hyperium mysorense (HM) (Hypericaceae) namely aerial parts (HMA), flowering tops (HMF), leaf (HML), root (HMR) and stem (HMS) were screened for its in vitro and in vivo anti cancer activities. The short term toxicity studies were carried out against Ehrlich Ascitic Carcinoma (EAC) cells. Different concentrations of the HM extracts (1000 µg/ml, 500 µg/ml, 250 µg/ml, 125 µg/ml, 62.5 µg/ml and 31.25 µg/ml) were tested against EAC cells and the viability of the cells were estimated by trypan blue dye exclusion method. HMF and HML showed better activity with CTC50 value of 375.39 ± 11.83 and 393.64 ± 12.28 µg/ml, respectively. In vivo antitumor studies were carried out for active HMF and HML extracts using EAC induced Swiss Albino mice model. Two different concentrations of HMF and HML were tested in vivo and compared with 5-Flurouracil (5-FU) as standard. The animals of the tumor control group inoculated with EAC survived for a period of 18.66 ± 0.65 days. The treatment with the HMF at 100 and 400 mg/kg increased the Average life span (ALS) of animals by 22.33 ± 1.28 and 26.16 ± 1.75 (p≪0.01) days, respectively. HML at a dose of 100 and 400 mg/kg increased the ALS of animals by 19.50 ± 1.73 and 23.50 ± 1.18 days, respectively. The standard 5-FU at 20 mg/kg, significantly (p≪0.001) increased the life span to 30.33 ± 1.02 (p≪0.001) days.